Merck Canada

MERCK MAKING NEWS

Latest News

February 18, 2021
HADLIMA^® (adalimumab injection) Now Available for the Treatment of Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Adult Crohn’s Disease, Ulcerative Colitis, Hidradenitis Suppurativa, Plaque Psoriasis, Adult and Pediatric Uveitiss and men 9 - 45 years of age

February 10, 2021
Merck Canada Statement on STROMECTOL^® (ivermectin) use During the COVID-19 Pandemic

January 20, 2021
Merck Canada and MaRS Team Up to Launch Lung Cancer Innovation Challenge

October 15, 2020
Health Canada Approves KEYTRUDA^® (pembrolizumab) as First-line Treatment for Patients with Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma

September 24, 2020
NEXPLANON^® Contraceptive Arm Implant Now Available for Use in Canada

September 15, 2020
BRENZYS®️ (etanercept injection) now indicated for the Treatment of Plaque Psoriasis, Psoriatic Arthritis and Juvenile Idiopathic Arthritis

May 27, 2020
Merck announces three significant scientific efforts in the fight against COVID-19

May 4, 2020
Merck Canada announces expanded support for Canadian communities, patients and health care workers affected by COVID-19

April 3, 2020
Merck Canada stands alongside Innovative Medicines Canada and other company members in the campaign to help frontline-healthcare workers fight against COVID-19

Mar 13, 2020
Health Canada Approves KEYTRUDA^®️ (pembrolizumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)

Nov 18, 2019
Ontario and Quebec provide reimbursement for HIV therapies PIFELTRO^®️ (doravirine) and DELSTRIGO^®️ (doravirine/lamivudine/tenofovir disoproxil fumarate)

This website is designed to provide members of the media with quick and easy access to recent information about Merck. For additional information, please visit 'About Merck'.

MEDIA CENTRE

For journalists with a media inquiry, please contact us: 1-833-90MERCK (1-833-906-3725).

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.